Bryan Giraudo serves as Chief Operating Officer and Chief Financial Officer at Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for immuno-inflammatory diseases. In this dual role, he oversees all operational, financial, and strategic functions, including capital raising, budgeting, investor relations, and operational infrastructure to support the company's innovative pipeline. Giraudo's leadership has been instrumental in navigating Gossamer Bio through key milestones, such as clinical trial advancements and financial restructuring, positioning the company for sustained growth in the competitive biotech sector. With more than 25 years of experience in the biotechnology and pharmaceutical industries, Giraudo brings a proven track record of driving value creation through financings, mergers, and acquisitions. Prior to joining Gossamer Bio in 2021, he served as Chief Financial Officer at Relypsa, Inc., where he managed financial operations leading up to its $1.3 billion acquisition by Galapagos NV in 2016. Earlier, as Senior Vice President of Finance at MAP Pharmaceuticals, he played a key role in the company's $1 billion acquisition by Allergan plc in 2013, and held progressive finance leadership positions at Genentech, a member of the Roche Group. Giraudo's achievements include successfully executing multiple initial public offerings, debt financings exceeding $500 million, and strategic partnerships that have accelerated drug development timelines. A Certified Public Accountant with an MBA from the University of San Francisco and a BS in Accounting from San Jose State University, he is recognized for his expertise in biotech financial strategy and operational excellence, earning accolades such as being named one of the "Most Influential Corporate Directors" by the National Association of Corporate Directors.